Dr. GPCR Podcast << Back to podcast list Dr. Demet Araç About Dr. Dr. Demet Araç on the web University of Chicago Araç Laboratory Google Scholar Twitter Dr. recording of the podcast with Demet for the same purpose. • Demet will distribute information about Academic Backgrounds and Career Paths Discussion Demet and Yamina discussed their academic backgrounds GPCR Field and Naming Convention Discussion Demet and Yamina discussed the ongoing developments in the

< GPCR News < GPCRs in Oncology and Immunology GPR56 signaling pathway network and its dynamics in the mesenchymal transition of glioblastoma Published date November 19, 2023 Abstract "G protein-coupled ranging from development to cancer. Thus, based on transcriptomic, proteomic, and phosphoproteomic differential expression data of GPR56 plausible cross-connectivity across different axes attributable to GPR56 function.

Immunology CB2 stimulation of adipose resident ILC2s orchestrates immune balance and ameliorates type 2 diabetes mellitus Published date July 3, 2024 Abstract "Development of type 2 diabetes mellitus (T2DM) is associated with low-grade chronic type 2 inflammation and disturbance of glucose homeostasis. system, is expressed on both visceral adipose tissue (VAT)-derived murine and human ILC2s. GPCR Create an account and get our contributors articles in your inbox Subscribe to the Dr.

Dr. GPCR Podcast << Back to podcast list Dr. Kevin Pfleger About this episode Dr. I sat down with Kevin to chat about GPCRs, pharmacology, and his contributions to the field in both the Professor Pfleger has developed extensive expertise in profiling receptor binding and function at the Scientific Advisor to Dimerix, and co-founder of RAGE Biotech . Dr.

Dr. GPCR Podcast << Back to podcast list Dr. Richard Premont About Dr. Richard Premont "Dr. In 1992, he won a Helen Hay Whitney Foundation fellowship to support his post-doctoral work with Robert Lefkowitz and Marc Caron at Duke University. 2018 studying GPCRs and their signaling pathways in the liver and in liver disease. Dr. Richard Premont on the web Google Scholar LinkedIn Dr.

< GPCR News < GPCRs in Oncology and Immunology Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion Published date March 21, 2023 Abstract " Pancreatic ductal adenocarcinoma (PDAC Analysing the main members of the PDAC extracellular purinome using publicly available databases discerned Using genetic modification and pharmacological strategies we demonstrate mechanistically that this ATP-driven DNA-PAINT super-resolution fluorescence microscopy reveals that P2Y 2 regulates the amount and distribution

Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Register AGPCR Newsletter Dr Up About the venue Discover Cinvestav, the host venue for the upcoming workshop.

< GPCR News < GPCRs in Oncology and Immunology Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy Published date September 26, 2023 Abstract "Infections (CAR) T-cell therapy and risks may differ between the early and late periods. Infections were recorded until day 365, if patients experienced symptoms with a microbiologic diagnosis CAR T-cell therapy, with 42 early infectious events (days, 0-100), and 22 late infectious events (days

and Immunology Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer through disrupting TRAF6-TAB2-TAK1-JNK/p38 MAPK signaling Published date June 21, 2024 Abstract "Colorectal cancer (CRC G protein signaling (RGS) protein family modulators play essential role within regulating downstream disease-specific survival (DSS) and disease-free survival (DFS) compared to those with low RGS16 expression GPCR Create an account and get our contributors articles in your inbox Subscribe to the Dr.

Dr. GPCR Podcast << Back to podcast list Dr. Claudia Stäubert About Dr. They acknowledged the difficulty of distinguishing between different compounds and the effect of media They briefly touched upon the link between GPCRs and diseases, such as diabetes, but did not delve into detail. Developing a Research Ecosystem at GPCR University Yamina and Claudia discussed developing an ecosystem

Oncology and Immunology Systems modeling of oncogenic G-protein and GPCR signaling reveals unexpected differences in downstream pathway activation Published date July 16, 2024 Abstract "Mathematical models of biochemical promote the signaling phenotype that contributes to the disease. to uncover and explore multiple new areas for investigating this disease. GPCR Create an account and get our contributors articles in your inbox Subscribe to the Dr.

durable responses. Here, we cross-integrated large singe-cell RNA-sequencing datasets from CD8+ T cells covering 19 distinct These include EP2, EP4, A2AR, β1AR and β2AR, all of which promote T cell dysfunction. We also developed transgenic mice expressing a chemogenetic CD8-restricted Gαs-DREADD to activate CD8 These data indicate that Gαs-GPCRs are druggable immune checkpoints that might be targeted to enhance

Dr. GPCR Podcast << Back to podcast list Dr. Sudarshan Rajagopal About Dr. Sudarshan Rajagopal Dr. During his doctoral work in the lab of Prof. During his Cardiology fellowship, he trained in the lab of Dr. Robert J. causes right heart failure, and he serves as co-director of the Duke Pulmonary Vascular Disease Center Dr. Sudarshan Rajagopal on the web LinkedIn Website Google Scholar LinkedIn Dr.

Dr. GPCR Podcast << Back to podcast list Dr. Debbie Hay About this episode Dr. Debbie Hay is presently a professor at the Department of Pharmacology and Toxicology at the University Debbie obtained a Ph.D. in Molecular Pharmacology from Imperial College London in the UK. Dr. Research Gate Twitter Dr.

Dr. GPCR Podcast << Back to podcast list Dr. Stephen Ferguson About Dr. Stephen Ferguson Dr. He did B.Sc. in biology at McGill University and received his Ph.D. under the mentorship of Dr. Brian Collier in the Department of Pharmacology and Therapeutics at McGill University (1994). He did his postdoctoral training with Dr. Marc G. Dr.

Dr. GPCR Podcast << Back to podcast list Dr. John Janetzko About Dr. To further develop these ideas, I joined the lab of Dr. Dr. design them. Industry: Career Progression Discussion Yamina and John had a detailed discussion about the prospects

Dr. GPCR Podcast << Back to podcast list Dr. Kathryn E Livingston About Dr. Kathryn E Livingston Dr. Working under the supervision of Dr. Following this, Kathryn did a post-doctoral fellowship at UCSF in the laboratory of Dr. Dr. Kathryn E Livingston on the web LinkedIn ResearchGate Pubmed Google Scholar Dr.

Dr. GPCR Podcast << Back to podcast list Dr. GPCR podcast , your host and founder, Dr. This podcast is part of the Dr. discovery and improve human health. Dr. Yamina Berchiche on the web - Website - LinkedIn - PubMed - Twitter - Facebook - Dr.

Dr. GPCR Podcast << Back to podcast list Dr. Paul Insel About this episode Dr. Paul Insel is currently a Distinguished Professor of Pharmacology and the University of California San Diego. Dr. Google PubMed Dr.

Dr. GPCR Podcast << Back to podcast list Dr. Arthur Christopoulos About Dr. disease, obesity, diabetes, chronic pain and addiction. discovery. Dr. Postdoctoral Position, Scientific Dynamics, and New Drug Targets Arthur shared his decision to undertake

Dr. GPCR Podcast << Back to podcast list Self-Learning, Collaboration, and Delegation in Science with Dr. Badr Sokrat About Dr. compartments to trigger distinct signaling events. " Dr. Yamina will continue to develop and manage the Dr.

Dr. GPCR Podcast << Back to podcast list Dr. Prasenjit Saha About Dr. During my post-doctoral research, I was part of a study that identified the receptors of a novel human disease. This study demonstrated that PAG is a potential diagnostic marker for CVD as it causes serious fatal Dr. Prasenjit Saha on the web Google Scholar Pubmed LinkedIn Dr.

Program < Back to schedule Biased agonism at the GLP-1 receptor: from structure to animal models of disease Date & Time Friday, November 3rd / 11:05 AM Abstract Coming Soon About Patrick Sexton " Patrick Sexton is a NHMRC Senior Principal Research Fellow and Director, ARC Centre for Cryo-electron Microscopy of GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases This pathway is implicated in mechanisms related to many diseases, such as cancer, psoriasis, multiple To date, there are no drugs against CCR6 approved, and the development of small molecules against CCR6 is complicated due to the difficulty in screenings. GPCR Create an account and get our contributors articles in your inbox Subscribe to the Dr.

"Dr Louis Gendron, PhD is tenured Professor and Chair of the Department of Pharmacology-Physiology at the Université de Sherbrooke. Dr Gendron is co-director of the FRQS-funded Quebec Pain Research Network and the Editor-in-Chief in LinkedIn Twitter Dr. du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

Dr. GPCR Podcast << Back to podcast list Dr. Stuart Maudsley About Dr. Following his Ph.D., Dr. novel longevity/disease-regulating compounds with multidimensional disease efficacy profiles. Dr. Reddit Dr.

< GPCR News < GPCRs in Oncology and Immunology Enterococcus-derived tyramine hijacks α2A-adrenergic receptor disease (IBD) is characterized by dysbiosis of the gut microbiota and dysfunction of intestinal stem However, the direct interactions between IBD microbial factors and ISCs are undescribed. tyrosine decarboxylase (tyrDC), serves as a microbial ligand for ADRA2A. impairing epithelial regeneration and exacerbating DSS-induced colitis through ADRA2A.

measures the missense tolerance ratio (MTR) using a three-dimensional (3D) structure (3DMTR). ( P < 0.05) in each dataset. were selected to define the functional phenotype. In downstream cAMP measurement, tolerant RGS14-D137Y and RGS10-S64T and intolerant RGS10-K89M resulted We used the novel bioinformatics tool three-dimensional missense tolerance ratio (3DMTR) to define regions